Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
RegulatoryWatchNotablemateriality 61 out of 100
What happened
FactPendency of Litigation(s)/dispute(s) or the outcome impacting the Company. litigation is filed. brief details of dispute/litigation.
Why it matters
CapitSignal interpretationLitigation creates a contingent liability that is not in reported profit until it crystallises.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedEarlierQ2 FY26
AarƟ Drugs posted revenue of Rs. 652.9 crore in Q2 FY26, growing 9% year-on-year, with EBITDA of Rs. 84.4 crore, up 23%, with margin at 12.9%.
NowQ2 FY26
For H1 FY26, revenue was Rs. 1,243.7 crore, up 8% year-on-year, with EBITDA of Rs. 158.8 crore, up 18% with margin at 12.8%.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved 90.49%.confidence 60%
Watch next
Fact- Amount claimed against the company
- Whether a provision has been made
- Next hearing or order date
- We expect to make further progress on utilization ramp-up during FY 2027. (management committed by FY27)
- For FY '26, we feel around INR10 crores to INR15 crores might -- of benefit might come in this year itself. (management committed by FY26)
Evidence
- Aarti Drugs Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company(opens the original filing in a new tab)
- Earlier statement · Q2 FY26
- Latest statement · Q2 FY26
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- LITIGATION base 56; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%